|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
Podocalyxin (Podxl) is a CD34 orthologue and cell surface sialomucin reported to have roles in renal podocyte diaphragm slit development; vascular cell integrity; and the progression of blood, breast, and prostate cancers.
|
28408238 |
2017 |
|
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of podocalyxin in prostate cancer renders the protein a putative immunohistochemical marker of prostate cancer that may contribute to stratification of patients for optimal treatment.
|
30396958 |
2018 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33.
|
16434482 |
2006 |
|
Prostatic Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Podocalyxin expression and H-scores were considerably higher in prostate tumors compared to normal tissues.
|
30396958 |
2018 |
|
Nephrosis, congenital
|
0.310 |
Biomarker
|
disease |
BEFREE |
Loss of podocalyxin causes a novel syndromic type of congenital nephrotic syndrome.
|
29244787 |
2017 |
|
PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Discovery of a frameshift mutation in podocalyxin-like (PODXL) gene, coding for a neural adhesion molecule, as causal for autosomal-recessive juvenile Parkinsonism.
|
26864383 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a role in lumen formation during polarized epithelial morphogenesis, is an independent indicator of poor prognosis in a number of epithelial cancers, including those that arise in the breast.
|
26796961 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These observations suggest that PCLP1 expression could provide a mechanism to evade the immune response, thereby promoting metastatic progression of cancer.
|
26276714 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Podocalyxin is an anti-adhesive mucin-like transmembrane sialoglycoprotein that has been implicated in the development of aggressive forms of cancer.
|
18639524 |
2008 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cell-adhesion glycoprotein PODXL is associated with an aggressive tumor phenotype in several forms of cancer.
|
27461278 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the initial discovery of podocalyxin in a cancerous stem cell, numerous new studies have identified podocalyxin in many different human cancers and in embryonic stem cells lines (ES) derived from human embryos.
|
17124010 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
|
31083655 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis of PODXL showed that the expression of PODXL protein in cancer tissues is higher than that in adjacent tissues.
|
31669641 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
|
21383689 |
2011 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Disease free survival and cancer-specific survival were significantly worse for patients whose tumors overexpressed PODXL.
|
28004467 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, PODXL plays a critical role in cancer stemness, invasiveness, and sensitivity to chemotherapies in colon cancer HCT15 cells.
|
28946619 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Podocalyxin (PCLP1) is a CD34-related sialomucin expressed by some normal cells and a variety of malignant tumors, including leukemia, and associated with the most aggressive cancers and poor clinical outcome.
|
29245936 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein sequence data obtained from purified podocalyxin protein isolated from embryonal carcinoma cancer stem cells reveals peptide sequence data for the glucose-3-transporter.
|
20599725 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Podocalyxin (PODXL) has been found to increase the aggressive phenotype of a number of cancers, including astrocytoma.
|
24788963 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
|
21383689 |
2011 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Forced overexpression of podocalyxin caused cohesive clusters of epithelial MCF-7 breast tumor cells to bud off from the primary tumor and collectively invade the stroma of the mouse mammary gland in vivo.
|
26796961 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In vitro experiments showed the knockdown of PODXL suppressed reduces CRC tumor growth, metastasis and EMT, and promoted apoptosis.
|
30575907 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
High PODXL expression was associated with poor prognosis features including large tumor size, high histological grade, estrogen and progesterone receptor negativity, and with clinical alterations characteristic of the basal-like breast cancer phenotype.
|
23288345 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Likewise, in competitive tumor engraftment assays where we injected a 50:50 mixture of control and shPODXL (short-hairpin RNA targeting PODXL)-expressing cells, we found that podocalyxin-deficient cells exhibited a striking decrease in the ability to form clonal tumors in the lung, liver and bone marrow.
|
25887862 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33.
|
16434482 |
2006 |